Our results showed that the HCC patients within low EGFL8 expression group had either worse overall survival (median survival time, 420 days versus 985 days, P = 0.0140; Fig. 1c) or worse progression free survival (median progression free survival time, 380 days versus 760 days, P = 0.0365; Fig. 1d) than those within high EGFL8 expression group. The gene discussed is EGFL8; the disease is hepatocellular carcinoma.